Nooter K, Sonneveld P, Martens A, Hagenbeek A, Schultz F
Eur J Cancer Clin Oncol. 1986 Jul;22(7):801-6. doi: 10.1016/0277-5379(86)90366-4.
The pharmacokinetic and cytotoxic behaviour of daunomycin in rats (7.5 mg/kg) when administered as an i.v. bolus injection were compared with those of a 3-hr infusion. After an i.v. bolus injection, the plasma drug levels decreased triphasically (t1/2 alpha = 0.8 min, t1/2 beta = 29.6 min and t1/2 gamma = 9.9 hr). The organs showed two types of concentration/time curves. One was found in the lungs, liver, kidneys and heart and had an initial high drug concentration followed by a relatively rapid elimination. The other was shown by the hemopoietic tissues (spleen and bone marrow): the drug uptake phase lasted longer (about 1.5 hr) and the elimination was slower. In general, daunomycin infusion led to substantially lower plasma and tissue levels, including in the heart, liver and kidneys. Again the hemopoietic tissues behaved in a different way: in spleen and bone marrow almost equal drug levels were obtained after daunomycin infusion as compared to a bolus injection. The myelotoxicity after daunomycin treatment was assessed by CFU-S (colony forming units-spleen) survival: the bolus injection killed as many CFU-S as did infusion (mean +/- S.D.: 11.8 +/- 5.3 CFU-S survival versus mean +/- S.D.: 13.5 +/- 2.4). Thus, it can be predicted that daunomycin infusion will lead to less cardiotoxicity but to an equal bone marrow suppression.
将柔红霉素以静脉推注(7.5mg/kg)和3小时静脉输注的方式给予大鼠,比较其药代动力学和细胞毒性行为。静脉推注后,血浆药物水平呈三相下降(t1/2α = 0.8分钟,t1/2β = 29.6分钟,t1/2γ = 9.9小时)。各器官呈现出两种浓度/时间曲线类型。一种出现在肺、肝、肾和心脏,初始药物浓度较高,随后消除相对较快。另一种由造血组织(脾和骨髓)呈现:药物摄取阶段持续时间较长(约1.5小时),消除较慢。总体而言,柔红霉素输注导致血浆和组织水平显著降低,包括心脏、肝脏和肾脏。造血组织的表现再次不同:柔红霉素输注后,脾和骨髓中的药物水平与推注相比几乎相等。通过CFU-S(脾集落形成单位)存活情况评估柔红霉素治疗后的骨髓毒性:推注杀死的CFU-S数量与输注相同(平均值±标准差:11.8±5.3 CFU-S存活,而平均值±标准差:13.5±2.4)。因此,可以预测柔红霉素输注将导致较低的心脏毒性,但骨髓抑制程度相同。